Первичный гиперальдостеронизм как возможная причина резистентного течения артериальной гипертонии - Журнал Системные Гипертензии Том 17, №4 (2020)
Первичный гиперальдостеронизм как возможная причина резистентного течения артериальной гипертонии
Чихладзе Н.М. Первичный гиперальдостеронизм как возможная причина резистентного течения артериальной гипертонии. Системные гипертензии. 2020; 17 (4): 20–23. DOI: 10.26442/2075082X.2020.4.200338
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзоре рассматривается распространенность резистентного течения артериальной гипертонии (АГ) при низкорениновых формах гиперальдостеронизма. Проанализированы возможные причины существующих различий в данных по распространенности гетерогенной группы первичного гиперальдостеронизма (ПГА) при резистентном течении АГ. Рассмотрены категории пациентов высокого риска развития ПГА в зависимости от тяжести течения АГ. По результатам проведенных исследований, включая собственные данные, показано, что в большинстве случаев опухолевые и гиперпластические формы ПГА ассоциированы с тяжелым и резистентным течением АГ, обосновывается важность проведения диагностического скрининга у этой категории пациентов.
Ключевые слова: первичный гиперальдостеронизм, резистентная артериальная гипертония, распространенность.
Key words: primary hyperaldosteronism, resistant arterial hypertension, prevalence.
Ключевые слова: первичный гиперальдостеронизм, резистентная артериальная гипертония, распространенность.
________________________________________________
Key words: primary hyperaldosteronism, resistant arterial hypertension, prevalence.
Список литературы
1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. Eur Heart J 2018; 39: 3021–104.
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–26.
3. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42.
4. Petramala L, Olmati F, Galassi M et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Italian Journal of Medicine 2017; 11 (4): 380–7.
5. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
6. Strauch B, Zelinka T, Hampf M. et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–52.
7. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational. Lancet 2008; 371 (9628): 1921–6.
8. Käyser SC, Dekkers T, Groenewoud HJ et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101 (7): 2826–35.
9. Monticone S, Burrello J, Tizzani D et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69 (14): 1811–20.
10. Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
11. Самедова Х.Ф., Чихладзе Н.М., Блинова Е.В. и др. Оценка функционального состояния миокарда у больных артериальной гипертонией на фоне гиперальдостеронизма с использованием ортогональной электрокардиографии. Кардиоваскулярная терапия и профилактика. 2006; 5 (2): 15–9.
[Samedova Kh.F., Chikhladze N.M., Blinova E.V. et al. Otsenka funktsional'nogo sostoianiia miokarda u bol'nykh arterial'noi gipertoniei na fone giperal'dosteronizma s ispol'zovaniem ortogonal'noi elektrokardiografii. Kardiovaskuliarnaia terapiia i profilaktika. 2006; 5 (2): 15–9 (in Russian).]
12. Stowasser M, Bachmann AW, Huggard PR et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160–6.
13. Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018; 90 (9): 115–22.
[Chikhladze N.M., Favorova O.O., Chazova I.E. Familial type I hyperaldosteronism: clinical observation and literature review. Therapeutic Archive. 2018; 90 (9): 115–22 (in Russian).]
14. Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98–103.
15. Sang X, Jiang Y, Wang W et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31 (7): 1465–72.
16. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
17. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45 (8): 1243–8.
18. Jaffe G, Gray Z, Krishna G et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension. A Cohort Study. Hypertension 2020; 75 (3): 650–9.
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–26.
3. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42.
4. Petramala L, Olmati F, Galassi M et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Italian Journal of Medicine 2017; 11 (4): 380–7.
5. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
6. Strauch B, Zelinka T, Hampf M. et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–52.
7. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational. Lancet 2008; 371 (9628): 1921–6.
8. Käyser SC, Dekkers T, Groenewoud HJ et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101 (7): 2826–35.
9. Monticone S, Burrello J, Tizzani D et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69 (14): 1811–20.
10. Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
11. Samedova Kh.F., Chikhladze N.M., Blinova E.V. et al. Otsenka funktsional'nogo sostoianiia miokarda u bol'nykh arterial'noi gipertoniei na fone giperal'dosteronizma s ispol'zovaniem ortogonal'noi elektrokardiografii. Kardiovaskuliarnaia terapiia i profilaktika. 2006; 5 (2): 15–9 (in Russian).
12. Stowasser M, Bachmann AW, Huggard PR et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160–6.
13. Chikhladze N.M., Favorova O.O., Chazova I.E. Familial type I hyperaldosteronism: clinical observation and literature review. Therapeutic Archive. 2018; 90 (9): 115–22 (in Russian).
14. Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98–103.
15. Sang X, Jiang Y, Wang W et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31 (7): 1465–72.
16. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
17. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45 (8): 1243–8.
18. Jaffe G, Gray Z, Krishna G et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension. A Cohort Study. Hypertension 2020; 75 (3): 650–9.
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–26.
3. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42.
4. Petramala L, Olmati F, Galassi M et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Italian Journal of Medicine 2017; 11 (4): 380–7.
5. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
6. Strauch B, Zelinka T, Hampf M. et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–52.
7. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational. Lancet 2008; 371 (9628): 1921–6.
8. Käyser SC, Dekkers T, Groenewoud HJ et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101 (7): 2826–35.
9. Monticone S, Burrello J, Tizzani D et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69 (14): 1811–20.
10. Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
11. Самедова Х.Ф., Чихладзе Н.М., Блинова Е.В. и др. Оценка функционального состояния миокарда у больных артериальной гипертонией на фоне гиперальдостеронизма с использованием ортогональной электрокардиографии. Кардиоваскулярная терапия и профилактика. 2006; 5 (2): 15–9.
[Samedova Kh.F., Chikhladze N.M., Blinova E.V. et al. Otsenka funktsional'nogo sostoianiia miokarda u bol'nykh arterial'noi gipertoniei na fone giperal'dosteronizma s ispol'zovaniem ortogonal'noi elektrokardiografii. Kardiovaskuliarnaia terapiia i profilaktika. 2006; 5 (2): 15–9 (in Russian).]
12. Stowasser M, Bachmann AW, Huggard PR et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160–6.
13. Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018; 90 (9): 115–22.
[Chikhladze N.M., Favorova O.O., Chazova I.E. Familial type I hyperaldosteronism: clinical observation and literature review. Therapeutic Archive. 2018; 90 (9): 115–22 (in Russian).]
14. Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98–103.
15. Sang X, Jiang Y, Wang W et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31 (7): 1465–72.
16. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
17. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45 (8): 1243–8.
18. Jaffe G, Gray Z, Krishna G et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension. A Cohort Study. Hypertension 2020; 75 (3): 650–9.
________________________________________________
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–26.
3. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125 (13): 1635–42.
4. Petramala L, Olmati F, Galassi M et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Italian Journal of Medicine 2017; 11 (4): 380–7.
5. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
6. Strauch B, Zelinka T, Hampf M. et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–52.
7. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational. Lancet 2008; 371 (9628): 1921–6.
8. Käyser SC, Dekkers T, Groenewoud HJ et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101 (7): 2826–35.
9. Monticone S, Burrello J, Tizzani D et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69 (14): 1811–20.
10. Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
11. Samedova Kh.F., Chikhladze N.M., Blinova E.V. et al. Otsenka funktsional'nogo sostoianiia miokarda u bol'nykh arterial'noi gipertoniei na fone giperal'dosteronizma s ispol'zovaniem ortogonal'noi elektrokardiografii. Kardiovaskuliarnaia terapiia i profilaktika. 2006; 5 (2): 15–9 (in Russian).
12. Stowasser M, Bachmann AW, Huggard PR et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160–6.
13. Chikhladze N.M., Favorova O.O., Chazova I.E. Familial type I hyperaldosteronism: clinical observation and literature review. Therapeutic Archive. 2018; 90 (9): 115–22 (in Russian).
14. Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98–103.
15. Sang X, Jiang Y, Wang W et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31 (7): 1465–72.
16. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
17. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45 (8): 1243–8.
18. Jaffe G, Gray Z, Krishna G et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension. A Cohort Study. Hypertension 2020; 75 (3): 650–9.
Авторы
Н.М. Чихладзе*
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
*novella.cardio@mail.ru
Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology, Moscow, Russia
*novella.cardio@mail.ru
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
*novella.cardio@mail.ru
________________________________________________
Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology, Moscow, Russia
*novella.cardio@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.